Existing and emerging therapies for managing constipation and diarrhea
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Functional bowel disorders (i.e., constipation and diarrhea) are characterized by abdominal pain, bloating, distention, and/or bowel habit abnormalities in the absence of obvious anatomic or physiologic abnormalities on routine diagnostic tests. These symptoms are attributable to gastrointestinal sensorimotor dysfunctions resulting from peripheral and/or central mechanisms. Available drugs target the underlying bowel disturbance (ie, constipation, diarrhea, or both), supplemented when necessary by management of pain. Osmotic and stimulant laxatives, secretagogues, and serotonin 5-HT4 receptor agonists are approved for treating constipation. Loperamide, anticholinergic agents, rifaximin, bile-acid binding agents, eluxadoline, and clonidine are used to treat diarrhea. Several exciting new compounds, some of which have been evaluated in humans, are currently under development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 1×
“7%) and also at 10 weeks posttreatment.[19] Adequate relief was defined by an affirmative response to the question: “In regard to all your symptoms of IBS, as compared with the way you felt before you started the study medication, have you, in the past 7 days, had adequate relief of your IBS symptoms?” Subsequently, t…”
BackgroundRole for protease activity in visceral pain in irritable bowel syndrome
Cenac, N., Andrews, C. N., Holzhausen, M., Chapman, K., Cottrell, G., Andrade-Gordon, P., Steinhoff, M., Barbara, G., Beck, P., Bunnett, N. W., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29255 · Cited by 591 · cited 1×
“In animal models of visceral hypersensitivity, PAR-2 antagonists and a PAR-4 agonist reversed colonic visceral hypersensitivity induced by supernatants from colonic biopsies from IBS patients.[39,40] Perhaps proteases such as trypsin 3 released from the epithelium of IBS patients activated sensory nerve endings.”
BackgroundWouters, M. M., Balemans, D., Van Wanrooy, S., Dooley, J., Cibert-Goton, V., Alpizar, Y. A., Valdez-Morales, E. E., Nasser, Y., Van Veldhoven, P. P., Vanbrabant, W., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.034 · Cited by 372 · cited 2×
“[35,36] In a 12-week, double-blind, placebo-controlled study, the HRH1 receptor antagonist ebastine (20mg once daily) reduced visceral hypersensitivity, and improved symptoms, including abdominal pain, versus placebo.[35] (Table 1).”
BackgroundSelf-citationEluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334 · cited 2×
“Six weeks after the first retreatment, all patients were retreated again; again, the response to rifaximin was greater than placebo.[16] Adverse events, primarily headache, upper respiratory tract infection, and abdominal pain, were uncommon and similar between groups.”
BackgroundResultPeripheral mechanisms in irritable bowel syndrome
Camilleri, M. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1207068 · Cited by 300
Tack, J., Camilleri, M., Chang, L., Chey, W. D., Galligan, J. J., Lacy, B. E., Müller‐Lissner, S., Quigley, E. M. M., Schuurkes, J., De Maeyer, J. H., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05011.x · Cited by 286
Self-citationFord, A. C., Brandt, L. J., Young, C., Chey, W. D., Foxx-Orenstein, A. E., & Moayyedi, P. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.223 · Cited by 261 · cited 1×
“Serotonin 5HT3 antagonists The 5HT3-antagonist alosetron reduces abdominal pain and diarrhea in IBS-D patients.[22] Because it can cause, albeit rarely, severe constipation and ischemic colitis, it is approved for limited use, including the United States.”
BackgroundEpithelial expression and function of trypsin-3 in irritable bowel syndrome
Rolland-Fourcade, C., Denadai-Souza, A., Cirillo, C., Lopez, C., Jaramillo, J. O., Desormeaux, C., Cenac, N., Motta, J.-P., Larauche, M., Taché, Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312094 · Cited by 126
Fukudo, S., Kinoshita, Y., Okumura, T., Ida, M., Akiho, H., Nakashima, Y., Nishida, A., & Haruma, K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.10.047 · Cited by 125
Annaházi, A., Gecse, K., Dabek, M., Ait-Belgnaoui, A., Rosztóczy, A., Róka, R., Molnár, T., Theodorou, V., Wittmann, T., Bueno, L., et al. (2009) · Pain · doi:10.1016/j.pain.2009.04.017 · Cited by 112
Chey, W. D., Lembo, A. J., & Rosenbaum, D. P. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.41 · Cited by 102
Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?
Aziz, I., Törnblom, H., & Simrén, M. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000348 · Cited by 45
Cited by
Sharkey, K. A., & Mawe, G. M. (2023) · Physiological Reviews · doi:10.1152/physrev.00018.2022 · Cited by 390
Bharucha, A. E., & Wald, A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.031 · Cited by 238
Self-citationZhang, C., Jiang, J., Tian, F., Zhao, J., Zhang, H., Zhai, Q., & Chen, W. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.01.005 · Cited by 131
Haggie, P. M., Cil, O., Lee, S., Tan, J.-A., Rivera, A. A., Phuan, P.-W., & Verkman, A. S. (2018) · JCI Insight · doi:10.1172/jci.insight.121370 · Cited by 56
“Three prosecretory drugs that activate Cl– channels have been approved: lubiprostone, a prostaglandin derivative that indirectly activates CFTR and chloride channel 2 (ClC-2); linaclotide, a peptide agonist of the guanylate cyclase C receptor that indirectly activates CFTR; and plecanatide, a uroguanylin analog that a…”
BackgroundMcClurg, D., Booth, L., & Herrero-Fresneda, I. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000267 · Cited by 18
Metadata
- Authors
- Bharucha, A. E., Wouters, M. M., & Tack, J.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 37
- Pages
- 158-166
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2770069383
- Cited by
- 43
- References
- 12
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.